In December, Amgen announced a definitive agreement to acquire Horizon Therapeutics HZNP for $116.5 per share in cash or $27.8 billion. The acquisition will add several first-in-class early-in-lifecycle biologic drugs like Tepezza, Krystexxa and Uplizna to Amgen's broad and diversified portfolio. The Horizon Therapeutics acquisition is expected to close in the first half of 2023.